Intracerebral hemorrhage (ICH)

Intracerebral Hemorrhage (ICH) Score

Initial care

  • airway
  • cardiovascular support
  • acute stroke care facility, ICU care

Reversal of anticoagulation & coagulopathy

Stop all anticoagulant and antiplatelet

  • Heparin associated bleed
    • Protamine sulfate: slow IV infusion (< 20 mg/minute and no more than 50 mg over any 10-minute period).
  • Warfarin associated ICH: ReverseWarfarin
  • NOAC associated ICH: Reverse NOAC
  • Severe coagulation factor deficiency or thrombocytopenia
    • appropriate factor replacement or platelet transfusion
  • Patient on antiplatelet therapy: platelet transfusions not indicated

Blood pressure management

  • For systolic blood pressure (SBP) 150 – 220 mmHg: acute lowering to 140 mmHg
  • For SBP >220 mmHg: consider SBP to 140 to 160 mmHg

Gerneral care:

  • = Intermittent pneumatic compression
  • = Normal saline initially
  • = Avoid Hypervolemia
  • = Treat sources of fever. Prophylactic antibiotic use does not improve outcomes
  • = Dysphagia, npo
  • = Treat Hyperglycemia, glucose level between 140 to 180 mg/dL
  • = Seizure management — risk of seizures 15 percent
    • Prophylactic seizure medication not indicated.

Intracranial pressure management

  • Head of the bed 30 degrees
  • Mild sedation, as needed
  • Avoid endotracheal tube holder and securement device ties, constrictive central line dressings
  • Avoid twisting of the head that might constrict cervical veins
  • Use normal saline initially; avoid hypotonic fluid
  • Glucocorticoids should NOT be used to lower the ICP
  • ICP monitoring:
    • if Glasgow Coma Scale (GCS) score <8
    • or clinical evidence of transtentorial herniation
    • or significant intraventricular hemorrhage or hydrocephalus
    • goal of cerebral perfusion pressure (CPP) of 50 to 70 mmHg.
  • Hydrocephalus: consider ventriculostomy
  • Hyperventilation
    • rapid lowering of ICP by inducing cerebral vasoconstriction
    • PaCO2 goal of >30 to 35 mmHg
    • More aggressive hyperventilation (ie, a PaCO2 of 26 to 30 mmHg) may result in brain ischemia and worse outcomes
  • Osmotic therapy
    • Mannitol: initial bolus of 0.5 to 1 g/kg IV, then 0.25 to 0.5 g/kg as needed, every four to twelve hours
      • monitor serum osmolality, goal 300 – 310 mosmol/kg
      • should not exceed 250 mg/kg every four hours; higher doses can cause acute renal failure.
    • Hypertonic saline: 3 percent, continuous infusion titrated to a sodium goal of approximately 145 to 155 mEq/L.
    • may cause circulatory overload and pulmonary edema, increased chloride burden, metabolic acidosis
  • = Pharmacologic coma.
    • Propofol:
      • – reduces intracranial pressure
      • – easily titrated
      • – short half-life.
      • – only for ventilated patients
      • – loading dose 1 – 3 mg/kg and continued as an infusion
      • – typically at 5 to 50 mcg/kg per minute, with a maximum dose of 200 µg/kg per minute.
      • – Hypotension is common; treat with intravenous fluids and/or vasopressors
      • – Propofol infusion syndrome: a rare complication with high doses >4 mg/kg per hour and prolonged use >48 hours
      • acute refractory bradycardia, metabolic acidosis, cardiovascular collapse, rhabdomyolysis, hyperlipidemia, renal failure, and hepatomegaly.
  • Neuromuscular blockade
    • – sometimes employed to reduce ICP in patients who are not responsive to analgesia and sedation alone
    • – – muscle activity can contribute to increased ICP

Indications for Surgery

  • Cerebellar hemorrhage
    • = cerebellar hemorrhage greater than 3 cm in diameter, or
    • deteriorating neurologically or
    • brainstem compression and/or hydrocephalus due to ventricular obstruction
  • Supratentorial hemorrhage
    • Surgical treatment is controversial;
    • Features that support surgery include
      • recent onset of hemorrhage, ongoing clinical deterioration, and location of the hematoma near the cortical surface.
    • Features in favor of less aggressive therapy:
      • serious concomitant medical problems, advanced age
      • stable clinical condition
      • remote onset of hemorrhage, involvement of the dominant hemisphere
      • inaccessibility of the hemorrhage

After acute phase

  • Early mobilization and rehabilitation
  • treating hypertension is the most important step to reduce ICH
  • stop smoking, heavy alcohol, and illicit drug use
  • treatment of obstructive sleep apnea
  • no compelling reason to discontinue statin
  • Resumption of antiplatelet therapy
    • probably safe to resume antiplatelet therapy after the acute phase
      • if blood pressure is controlled
      • indication for antiplatelet treatment is sufficiently strong
      • if potential benefit outweighs the increase in risk of recurrent ICH.
  • Cerebral amyloid angiopathy, aspirin use may be associated with a greater risk of recurrent ICH
  • Aspirin or antiplatelets for those patients with only an “average” risk of recurrent ischemic stroke}
    • “average” risk: hypertension, diabetes, hypercholesterolemia, and the absence of heart disease to be markers of average risk.
    • “above average risk”: Atrial fibrillation, cardiomyopathy, large vessel extracranial and intracranial stenoses, and malignancy may benefit from long-term antiplatelet therapy after ICH.

Resumption of anticoagulation

  • 2015 AHA/ASA guidelines: delay oral anticoagulants for at least four weeks after onset of the ICH

PROGNOSIS

  • Mortality and functional outcome
    • 30-day mortality 35 to 52 percent
    • Half of these deaths occur in the first two days
    • pooled 1 and 5 year survival: 46 and 29 percent respectively
    • Independent function at one year 17 – 25 percent (54 to 57 percent of survivors)

Risk factors for poor outcomes

  • Increasing age
  • Low Glasgow Coma Scale (GCS) score
  • High ICH volume
    • – volume of 60 cm3 or greater on initial CT and a GCS score < 8 has a 30-day mortality of 91 percent.
    • – volume less than 30 cm3 and a GCS score of nine or more predicted a 30-day mortality of 19 percent.
  • Intraventricular hemorrhage
  • Deep or infratentorial ICH location
  • Preceding oral anticoagulation therapy, and possibly antiplatelet therapy
  • Early neurologic deterioration within 48 hours
  • Hematoma growth — particularly within the first 24 hours
  • extensive white matter lesions on CT or MRI are associated with worse outcomes
  • ICH score: Add each category
    • GCS score 3 to 4 (= 2 points); GCS 5 to 12 (= 1 point) and GCS 13 to 15 (= 0 points)
    • ICH volume =30 cm3 (= 1 point), ICH volume <30 cm3 (= 0 points)
    • Intraventricular extension of hemorrhage present (= 1 point); absent (= 0 points)
    • Infratentorial origin yes (= 1 point); no (= 0 points)
    • Age =>80 (= 1 point); <80 (= 0 points)
  • Thirty-day mortality rates for ICH scores of 1, 2, 3, 4, and 5 were 13, 26, 72, 97, and 100 percent, respectively.
  • A modified ICH score using the National Institutes of Health Stroke Scale (NIHSS) score in place of the GCS score may be a better predictor of good outcome than the original ICH score

Risk factors for recurrent ICH

  • Risk of recurrent bleed 1-7%/year
  • Uncontrolled hypertension
  • Lobar location of initial ICH
  • Older age
  • male
  • Ongoing anticoagulation
  • Apolipoprotein E epsilon 2 or epsilon 4 alleles
  • Greater number of microbleeds on MRI
  • Ischemic stroke history
  • Black race or Hispanic ethnicity
Tags:,